Mutations in the maternal copy of the UBE3A gene cause a neurodevelopmental disorder known as Angelman syndrome. Drugs that activate the normally silenced paternal copy of this gene may be of therapeutic value. See Letter p.185
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Notes
*This article and the paper1 under discussion were published online on 21 December 2011.
References
Huang, H.-S. et al. Nature 481, 185–189 (2011).
Guy, J., Gan, J., Selfridge, J., Cobb, S. & Bird, A. Science 315, 1143–1147 (2007).
Weeber, E. J. et al. J. Neurosci. 23, 2634–2644 (2003).
Gammon, D. C. et al. Am. J. Health-Syst. Pharm. 63, 2083–2086 (2006).
Bird, L. M. et al. Am. J. Med. Genet. A 155, 2956–2963 (2011).
Williams, C. A., Driscoll, D. J. & Dagli, A. I. Genet. Med. 12, 385–395 (2010).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Beaudet, A. Drugs to awaken a paternal gene. Nature 481, 151–152 (2012). https://doi.org/10.1038/nature10784
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature10784
This article is cited by
-
Cross-Disorder Comparison of Four Neuropsychiatric CNV Loci
Current Genetic Medicine Reports (2014)
